Targeted therapy program for rectal cancer needs to be formulated according to the specific condition of patients and their own situation, and the attending doctor should be consulted.
Patients with advanced stage of rectal cancer can not be treated with radiotherapy, chemotherapy and other traditional treatment plans, but the efficiency and prognosis are not very satisfactory. Therefore, clinically, targeted drugs will be used to carry out targeted treatment to target a specific gene or fragment of the patient, so that the drugs can act on the tumor tissues directly to achieve the effect of killing cancer cells and controlling the condition.
Targeted drugs commonly used for rectal cancer include bevacizumab, regorafenib, cetuximab, furaquintinib, etc. They can be used as single drugs or combined with chemotherapy and radiotherapy for comprehensive treatment to enhance the overall treatment effect. However, the selection of the specific program needs to be formulated by professional doctors according to the patient’s condition and their own situation, and the drugs should be applied under the guidance of doctors.